Skip to main content
ORTHOCELL LIMITED logo

ORTHOCELL LIMITED — Investor Relations & Filings

Ticker · OCC ISIN · AU000000OCC6 ASX Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2025-08-28 Governance Information
Country AU Australia
Listing ASX OCC

About ORTHOCELL LIMITED

https://orthocell.com/

Orthocell Limited is a regenerative medicine company focused on the development and commercialization of innovative technologies for the repair and regeneration of human soft tissue. The company’s core product portfolio includes the CelGro platform, a naturally derived collagen medical device designed to facilitate tissue repair and reconstruction in applications such as dental bone and soft tissue regeneration, nerve repair, and tendon repair. Orthocell also specializes in advanced cellular therapies, notably Ortho-ATI (Autologous Tenocyte Implantation) for treating chronic tendon injuries and Ortho-ACI (Autologous Chondrocyte Implantation) for cartilage repair. These therapies utilize a patient's own cells to restore function and structure to damaged tissues. The company aims to provide restorative solutions that improve clinical outcomes and offer alternatives to traditional surgical interventions.

Recent filings

Filing Released Lang Actions
Appendix 4G 11 pages 365.4KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a detailed form used by ASX-listed entities to confirm compliance with corporate governance recommendations and to provide a key to where governance disclosures can be found. The document is not the corporate governance statement itself but a verification and key to disclosures related to governance. It is lodged alongside the annual report but is a separate compliance document. The content focuses on governance principles, board charters, diversity policies, evaluation processes, and committee disclosures, which aligns with governance information rather than a full annual report or other financial filings. The document length is substantial (15,000 characters), indicating it is not a brief announcement or certification. Therefore, the most appropriate classification is Governance Information (CGR).
2025-08-28 English
Investor Presentation Canaccord Annual Growth Conference 22 pages 1.7MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation from Orthocell Ltd, dated August 2025, focusing on the company's products, market position, financial highlights, board members, and commercial updates, particularly regarding the US FDA clearance and commercialization of their flagship product Remplir. It includes forward-looking statements, market data, revenue figures, and strategic plans. The content is structured as a presentation with slides, disclaimers, and visual data summaries. There is no indication that this is a formal regulatory filing like an annual or interim report, audit report, or earnings release. It is not a transcript of a call, nor a legal or governance document. The document is clearly intended for investors and stakeholders to provide a comprehensive update on the company's business and financial status, strategy, and market outlook. This matches the definition of an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2025-08-14 English
Remplir Commericalisation into $1.6B US Market Gathers Pace 2 pages 200.4KB
Capital/Financing Update Classification · 90% confidence The document is a press release dated 13 August 2025 from Orthocell Limited providing an update on the commercialisation progress of its product Remplir™ in the US market. It discusses sales, hospital approvals, shipments, and staffing related to the product launch. There are no financial statements, quarterly or annual results, or detailed financial data presented. The content is focused on business development and commercial progress rather than financial reporting. The document is a corporate announcement about commercial progress and market development rather than a financial report or regulatory filing. Therefore, it fits best into the category of a Capital/Financing Update (CAP) as it relates to commercialisation and market expansion activities which impact the company's capital and revenue prospects.
2025-08-12 English
Proposed issue of securities - OCC 6 pages 22.1KB
Capital/Financing Update Classification · 100% confidence The document is titled 'Appendix 3B - Proposed issue of securities' and details a proposed issue of new securities (options) by Orthocell Limited. It includes specifics about the number of securities, issue dates, terms, and conditions related to the placement or other type of issue. The document is an official announcement regarding the company's capital raising or securities issuance activity. There is no financial performance data, management discussion, or audit information. The content aligns with updates on company fundraising or capital structure changes. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length is 8943 characters, which is substantive and not merely a brief announcement or report publication notice.
2025-07-27 English
Option Terms and Conditions 4 pages 296.8KB
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the terms and conditions of options issued by Orthocell Limited. It includes specifics about the number of options, exercise price, expiry dates, and conditions for exercising the options. There is no financial performance data, earnings information, or management discussion. The content focuses on the capital structure and securities issuance terms, which aligns with announcements about capital changes or financing activities. The document is not a full financial report, earnings release, or regulatory filing but rather a capital/financing update related to option issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2025-07-27 English
Notification regarding unquoted securities - OCC 10 pages 27.1KB
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Appendix 3G - Notification of issue, conversion or payment up of unquoted equity securities' and details the issuance of new unquoted options by Orthocell Limited. It includes specifics such as the number of securities issued, exercise prices, expiry dates, and the purpose of the issue (options issued to consulting surgeons in lieu of payment of fees). The document is a formal notification to the ASX regarding securities issuance, consistent with regulatory filings about capital changes but does not itself constitute a full financial report or announcement of financial results. It is not an announcement of a report publication, nor a management or earnings report. The content aligns with announcements about share issues or capital changes. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length (over 10,000 characters) and detailed content support a high confidence in this classification.
2025-07-27 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.